Analysts Set Assertio Holdings, Inc. (NASDAQ:ASRT) Target Price at $18.00

Shares of Assertio Holdings, Inc. (NASDAQ:ASRT) have earned an average recommendation of “Hold” from the six brokerages that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and one has issued a buy recommendation on the company. The average 12 month target price among brokerages that have covered the stock in the last year is $18.00.

A number of equities analysts recently commented on ASRT shares. Zacks Research cut Assertio from a “strong-buy” rating to a “hold” rating in a report on Friday, March 6th. Wall Street Zen cut Assertio from a “buy” rating to a “hold” rating in a report on Saturday, March 21st. HC Wainwright reaffirmed a “neutral” rating and issued a $18.00 target price (down from $35.00) on shares of Assertio in a report on Thursday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Assertio in a research note on Wednesday, January 21st. Finally, Maxim Group lowered Assertio from a “strong-buy” rating to a “hold” rating in a research note on Thursday.

Assertio Stock Performance

NASDAQ:ASRT opened at $18.02 on Thursday. The business has a fifty day simple moving average of $13.97 and a two-hundred day simple moving average of $12.40. The company has a market capitalization of $116.23 million, a P/E ratio of -3.71 and a beta of 0.43. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.70 and a quick ratio of 1.51. Assertio has a 1 year low of $8.55 and a 1 year high of $20.45.

Assertio (NASDAQ:ASRT) last released its quarterly earnings results on Monday, March 16th. The company reported ($1.86) earnings per share for the quarter, beating the consensus estimate of ($3.05) by $1.19. Assertio had a negative return on equity of 30.26% and a negative net margin of 25.59%.The firm had revenue of $13.54 million for the quarter, compared to analysts’ expectations of $6.20 million. On average, analysts expect that Assertio will post -0.15 earnings per share for the current year.

Key Stories Impacting Assertio

Here are the key news stories impacting Assertio this week:

• Positive Sentiment: Wall Street price‑target aggregation highlights large upside potential (Zacks notes a ~115% implied upside based on analyst targets), which could attract speculative buying and longer‑term interest. Does Assertio (ASRT) Have the Potential to Rally 115.05% as Wall Street Analysts Expect?
• Positive Sentiment: Assertio has sold SYMPAZAN® and additional branded products to Cosette Pharmaceuticals — a portfolio monetization move that should generate cash and simplify the commercial footprint (potentially positive for near‑term liquidity and margins). Cosette Pharmaceuticals Expands Branded Portfolio through Acquisition of SYMPAZAN® and Additional Products from Assertio
• Neutral Sentiment: Assertio updated FY‑2026 guidance, issuing revenue guidance roughly in a $110–$125M range versus a ~$111M consensus — guidance is near street expectations but the company left EPS guidance unclear in public notes, so impact is muted until further clarity is provided.
• Neutral Sentiment: HC Wainwright reaffirmed a “neutral” rating and cut its price target to $18 (from $35). The reaffirmation keeps the stock in a hold/neutral bucket despite the lower target.
• Negative Sentiment: Lake Street Capital downgraded Assertio from “buy” to “hold” and slashed its price target to $18 from $45 — a sharp target cut that signals weaker analyst conviction and can pressure near‑term demand. Lake Street downgrades Assertio Holdings (ASRT)
• Negative Sentiment: Short interest rose meaningfully in March to ~301,837 shares (~4.9% of shares outstanding; ~1.4 days to cover), indicating increased bearish positioning that can amplify downward moves if sentiment deteriorates.
• Negative Sentiment: A shareholder class‑action firm announced an investigation related to Assertio’s sale to Garda Therapeutics (the deal would pay $18.00 cash plus a contingent value right), introducing legal and closing‑risk uncertainty. Shareholder Alert: Investigation of Assertio Holdings, Inc.
• Negative Sentiment: The stock moved lower after‑hours on reports of a discounted buyout/deal structure, which likely contributed to immediate selling pressure and the recent downgrades. ASRT stock drops after-hours on discounted buyout deal

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Nantahala Capital Management LLC grew its position in shares of Assertio by 4.4% during the second quarter. Nantahala Capital Management LLC now owns 8,810,073 shares of the company’s stock valued at $5,649,000 after purchasing an additional 370,311 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Assertio by 0.9% during the third quarter. Vanguard Group Inc. now owns 4,425,543 shares of the company’s stock valued at $3,899,000 after purchasing an additional 41,332 shares in the last quarter. GSA Capital Partners LLP grew its position in shares of Assertio by 536.0% during the third quarter. GSA Capital Partners LLP now owns 381,584 shares of the company’s stock valued at $336,000 after purchasing an additional 321,584 shares in the last quarter. Perritt Capital Management Inc grew its position in shares of Assertio by 51.6% during the third quarter. Perritt Capital Management Inc now owns 350,316 shares of the company’s stock valued at $309,000 after purchasing an additional 119,281 shares in the last quarter. Finally, Opaleye Management Inc. purchased a new position in shares of Assertio during the fourth quarter valued at about $2,585,000. Hedge funds and other institutional investors own 48.96% of the company’s stock.

Assertio Company Profile

Assertio Therapeutics, Inc, formerly known as Depomed, is a specialty pharmaceutical company focused on the development and commercialization of therapies for central nervous system (CNS) disorders, including neuropathic pain, migraine and breakthrough cancer pain. The company’s commercial portfolio includes three FDA-approved products—Qutenza (8% capsaicin) for postherpetic neuralgia, Butrans (buprenorphine) transdermal system for chronic pain and Onsolis (fentanyl buccal soluble film) for breakthrough cancer pain—which are marketed primarily in the United States under licensing agreements with global partners.

In addition to its marketed therapies, Assertio maintains a pipeline of preclinical and clinical-stage candidates targeting a range of pain and neurological conditions.